{"nctId":"NCT00507728","briefTitle":"Pharmacogenetics, Emotional Reactivity and Smoking","startDateStruct":{"date":"2005-12-08","type":"ACTUAL"},"conditions":["Tobacco Use Disorder","Smoking Cessation"],"count":646,"armGroups":[{"label":"Bupropion","type":"EXPERIMENTAL","interventionNames":["Drug: Bupropion","Behavioral: Smoking Cessation Counseling"]},{"label":"Varenicline","type":"EXPERIMENTAL","interventionNames":["Drug: Varenicline","Behavioral: Smoking Cessation Counseling"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Behavioral: Smoking Cessation Counseling"]}],"interventions":[{"name":"Bupropion","otherNames":["Wellbutrin","Wellbutrin SR","Zyban"]},{"name":"Varenicline","otherNames":["Chantix"]},{"name":"Placebo","otherNames":[]},{"name":"Smoking Cessation Counseling","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age: 18-65 years old\n2. Smoking: \\>/= 5 cigarettes per day within the 2 months preceding the screening visit and expired CO greater than or equal to 6 ppm.\n3. Able to follow verbal and written instructions in English and complete all aspects of the study\n4. Have an address and home telephone number where they may be reached\n5. Provide informed consent and agree to all assessments and study procedures\n6. Be the only participant in their household\n\nExclusion Criteria:\n\n1. Within the month immediately preceding the screening visit; use of any form of tobacco product other than cigarettes on 3 or more days within a week only if the individual refuses to refrain from non-cigarette tobacco use during the course of this study\n2. Within the month immediately preceding the screening visit; use of marijuana in any form on 3 or more days within a week\n3. Within the two weeks immediately preceding the screening visit, involvement on more than 3 days in any formal smoking cessation activities\n4. Current visual or auditory problems that in the opinion of the investigator would interfere with the completion of study assessments\n5. Treatment on a continuous basis within 2 weeks before the screening visit: any contraindicated medication for Varenicline or Bupropion.\n6. Uncontrolled hypertension or other major contraindications for Bupropion or Varenicline.\n7. Severe renal impairment (CR Clearance \\<30 ml/min/1.73 m2).\n8. Laboratory evaluations outside normal limits and of potential clinical significance in the opinion of the investigator\n9. Meet current criteria for psychiatric disorders or substance abuse as assessed by the MINI for items A, B, D, I, J, K, L, M and N, including a past manic or hypomanic episode as well as a lifetime psychotic disorder.\n10. Subject rated as moderate to high on suicidality as assessed by the MINI.\n11. Psychiatric hospitalization within 1 year of screening date.\n12. A positive urine pregnancy test during the screening period. Women who are two years post menopausal, one year post-tubal ligation, or who have had a partial or full hysterectomy will not be subject to a urine pregnancy test.\n13. Pregnant, breast-feeding, or of childbearing potential who is not protected by a medically acceptable, effective method of birth control while enrolled in the study\n14. Use of Varenicline or Bupropion within two weeks before the screening visit.\n15. History of hypersensitivity or allergic reaction to Varenicline, tricyclic antidepressant, Bupropion (Wellbutrin, Zyban) or similar chemical classes or any component of these formulations.\n16. Subject considered by the investigator as unsuitable candidate for receipt of an investigational drug, or unstable to be followed up throughout the entire duration of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Emotional Reactivity By Pharmacotherapy","description":"Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.6","spread":null},{"groupId":"OG001","value":"64.7","spread":null},{"groupId":"OG002","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"73.1","spread":null},{"groupId":"OG002","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"65.4","spread":null},{"groupId":"OG002","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"64.9","spread":null},{"groupId":"OG002","value":"72.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele","description":"The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.5","spread":null},{"groupId":"OG001","value":"69.9","spread":null},{"groupId":"OG002","value":"66.2","spread":null},{"groupId":"OG003","value":"66","spread":null},{"groupId":"OG004","value":"67.3","spread":null},{"groupId":"OG005","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":null},{"groupId":"OG001","value":"75.1","spread":null},{"groupId":"OG002","value":"78.6","spread":null},{"groupId":"OG003","value":"71.3","spread":null},{"groupId":"OG004","value":"74","spread":null},{"groupId":"OG005","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"71.3","spread":null},{"groupId":"OG003","value":"63.3","spread":null},{"groupId":"OG004","value":"68.5","spread":null},{"groupId":"OG005","value":"63.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null},{"groupId":"OG001","value":"67.2","spread":null},{"groupId":"OG002","value":"73.9","spread":null},{"groupId":"OG003","value":"61.2","spread":null},{"groupId":"OG004","value":"79.7","spread":null},{"groupId":"OG005","value":"67.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Smoking Abstinence at 3 Months","description":"Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":null},{"groupId":"OG001","value":"-0.01","spread":null},{"groupId":"OG002","value":"-0.008","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.004","spread":null},{"groupId":"OG001","value":"-0.009","spread":null},{"groupId":"OG002","value":"-0.007","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":null},{"groupId":"OG001","value":"-0.01","spread":null},{"groupId":"OG002","value":"-0.007","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.004","spread":null},{"groupId":"OG001","value":"-0.008","spread":null},{"groupId":"OG002","value":"-0.007","spread":null}]}]}]},{"type":"SECONDARY","title":"Smoking Abstinence at 3 Months by DRD2 A1 Allele","description":"Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":null},{"groupId":"OG001","value":"-0.004","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"-0.003","spread":null},{"groupId":"OG004","value":"-0.001","spread":null},{"groupId":"OG005","value":"-0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":null},{"groupId":"OG001","value":"-0.005","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"-0.004","spread":null},{"groupId":"OG004","value":"-0.001","spread":null},{"groupId":"OG005","value":"-0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":null},{"groupId":"OG001","value":"-0.005","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"-0.003","spread":null},{"groupId":"OG004","value":"-0.001","spread":null},{"groupId":"OG005","value":"-0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":null},{"groupId":"OG001","value":"-0.005","spread":null},{"groupId":"OG002","value":"0.001","spread":null},{"groupId":"OG003","value":"-0.002","spread":null},{"groupId":"OG004","value":"-0.001","spread":null},{"groupId":"OG005","value":"-0.003","spread":null}]}]}]},{"type":"SECONDARY","title":"Smoking Abstinence at 6 Months","description":"Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.007","spread":null},{"groupId":"OG001","value":"-0.002","spread":null},{"groupId":"OG002","value":"-0.006","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.008","spread":null},{"groupId":"OG001","value":"-0.003","spread":null},{"groupId":"OG002","value":"-0.005","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"-0.003","spread":null},{"groupId":"OG002","value":"-0.005","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.008","spread":null},{"groupId":"OG001","value":"-0.001","spread":null},{"groupId":"OG002","value":"-0.005","spread":null}]}]}]},{"type":"SECONDARY","title":"Abstinence at 6 Months by DRD2 A1 Allele","description":"Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":null},{"groupId":"OG001","value":"-0.001","spread":null},{"groupId":"OG002","value":"0.001","spread":null},{"groupId":"OG003","value":"-0.001","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"-0.005","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":null},{"groupId":"OG001","value":"-0.001","spread":null},{"groupId":"OG002","value":"0.001","spread":null},{"groupId":"OG003","value":"-0.002","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"-0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"-0.001","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"-0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":null},{"groupId":"OG001","value":"-0.001","spread":null},{"groupId":"OG002","value":"0.001","spread":null},{"groupId":"OG003","value":"-0.001","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"-0.004","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)","description":"Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.394","spread":null},{"groupId":"OG001","value":"4.222","spread":null},{"groupId":"OG002","value":"4.28","spread":null},{"groupId":"OG003","value":"4.41","spread":null},{"groupId":"OG004","value":"5.584","spread":null},{"groupId":"OG005","value":"5.752","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.218","spread":null},{"groupId":"OG001","value":"5.873","spread":null},{"groupId":"OG002","value":"6.587","spread":null},{"groupId":"OG003","value":"6.587","spread":null},{"groupId":"OG004","value":"7.785","spread":null},{"groupId":"OG005","value":"7.915","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.743","spread":null},{"groupId":"OG001","value":"3.407","spread":null},{"groupId":"OG002","value":"4.238","spread":null},{"groupId":"OG003","value":"3.935","spread":null},{"groupId":"OG004","value":"4.764","spread":null},{"groupId":"OG005","value":"4.951","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.646","spread":null},{"groupId":"OG001","value":"6.252","spread":null},{"groupId":"OG002","value":"6.814","spread":null},{"groupId":"OG003","value":"6.78","spread":null},{"groupId":"OG004","value":"9.024","spread":null},{"groupId":"OG005","value":"8.696","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.016","spread":null},{"groupId":"OG001","value":"10.707","spread":null},{"groupId":"OG002","value":"9.79","spread":null},{"groupId":"OG003","value":"11.082","spread":null},{"groupId":"OG004","value":"11.207","spread":null},{"groupId":"OG005","value":"11.044","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.246","spread":null},{"groupId":"OG001","value":"3.738","spread":null},{"groupId":"OG002","value":"4.005","spread":null},{"groupId":"OG003","value":"4.338","spread":null},{"groupId":"OG004","value":"5.293","spread":null},{"groupId":"OG005","value":"5.865","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.721","spread":null},{"groupId":"OG001","value":"8.153","spread":null},{"groupId":"OG002","value":"9.672","spread":null},{"groupId":"OG003","value":"9.528","spread":null},{"groupId":"OG004","value":"9.078","spread":null},{"groupId":"OG005","value":"8.629","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)","description":"Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.507","spread":null},{"groupId":"OG001","value":"37.315","spread":null},{"groupId":"OG002","value":"36.429","spread":null},{"groupId":"OG003","value":"35.281","spread":null},{"groupId":"OG004","value":"33.672","spread":null},{"groupId":"OG005","value":"33.984","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.93","spread":null},{"groupId":"OG001","value":"14.98","spread":null},{"groupId":"OG002","value":"15.782","spread":null},{"groupId":"OG003","value":"16.385","spread":null},{"groupId":"OG004","value":"18.017","spread":null},{"groupId":"OG005","value":"18.902","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)","description":"Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.084","spread":null},{"groupId":"OG001","value":"6.847","spread":null},{"groupId":"OG002","value":"7.588","spread":null},{"groupId":"OG003","value":"8.362","spread":null},{"groupId":"OG004","value":"8.65","spread":null},{"groupId":"OG005","value":"10.799","spread":null}]}]}]},{"type":"SECONDARY","title":"Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales","description":"Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.895","spread":null},{"groupId":"OG001","value":"2.591","spread":null},{"groupId":"OG002","value":"4.064","spread":null},{"groupId":"OG003","value":"3.369","spread":null},{"groupId":"OG004","value":"3.025","spread":null},{"groupId":"OG005","value":"3.515","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.819","spread":null},{"groupId":"OG001","value":"2.155","spread":null},{"groupId":"OG002","value":"2.519","spread":null},{"groupId":"OG003","value":"2.723","spread":null},{"groupId":"OG004","value":"3.575","spread":null},{"groupId":"OG005","value":"3.246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.612","spread":null},{"groupId":"OG001","value":"1.694","spread":null},{"groupId":"OG002","value":"1.988","spread":null},{"groupId":"OG003","value":"1.79","spread":null},{"groupId":"OG004","value":"1.808","spread":null},{"groupId":"OG005","value":"1.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.912","spread":null},{"groupId":"OG001","value":"1.703","spread":null},{"groupId":"OG002","value":"4.096","spread":null},{"groupId":"OG003","value":"1.955","spread":null},{"groupId":"OG004","value":"3.711","spread":null},{"groupId":"OG005","value":"2.783","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.531","spread":null},{"groupId":"OG001","value":"3.952","spread":null},{"groupId":"OG002","value":"4.564","spread":null},{"groupId":"OG003","value":"6.628","spread":null},{"groupId":"OG004","value":"4.486","spread":null},{"groupId":"OG005","value":"4.673","spread":null}]}]}]},{"type":"SECONDARY","title":"Skin Conductance Response","description":"Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.301","spread":null},{"groupId":"OG001","value":"2.016","spread":null},{"groupId":"OG002","value":"2.275","spread":null},{"groupId":"OG003","value":"1.797","spread":null},{"groupId":"OG004","value":"2.272","spread":null},{"groupId":"OG005","value":"2.443","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.295","spread":null},{"groupId":"OG001","value":"1.969","spread":null},{"groupId":"OG002","value":"2.31","spread":null},{"groupId":"OG003","value":"1.695","spread":null},{"groupId":"OG004","value":"2.355","spread":null},{"groupId":"OG005","value":"2.485","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.256","spread":null},{"groupId":"OG001","value":"1.984","spread":null},{"groupId":"OG002","value":"2.299","spread":null},{"groupId":"OG003","value":"1.7","spread":null},{"groupId":"OG004","value":"2.296","spread":null},{"groupId":"OG005","value":"2.565","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.261","spread":null},{"groupId":"OG001","value":"2.017","spread":null},{"groupId":"OG002","value":"2.369","spread":null},{"groupId":"OG003","value":"1.699","spread":null},{"groupId":"OG004","value":"2.362","spread":null},{"groupId":"OG005","value":"2.559","spread":null}]}]}]},{"type":"SECONDARY","title":"Heart Rate Response","description":"Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.731","spread":null},{"groupId":"OG001","value":"68.652","spread":null},{"groupId":"OG002","value":"71.427","spread":null},{"groupId":"OG003","value":"69.836","spread":null},{"groupId":"OG004","value":"65.966","spread":null},{"groupId":"OG005","value":"65.276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.562","spread":null},{"groupId":"OG001","value":"68.078","spread":null},{"groupId":"OG002","value":"71.077","spread":null},{"groupId":"OG003","value":"69.595","spread":null},{"groupId":"OG004","value":"65.768","spread":null},{"groupId":"OG005","value":"65.569","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.151","spread":null},{"groupId":"OG001","value":"68.711","spread":null},{"groupId":"OG002","value":"71.518","spread":null},{"groupId":"OG003","value":"70.404","spread":null},{"groupId":"OG004","value":"65.787","spread":null},{"groupId":"OG005","value":"65.927","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.621","spread":null},{"groupId":"OG001","value":"68.969","spread":null},{"groupId":"OG002","value":"71.706","spread":null},{"groupId":"OG003","value":"70.234","spread":null},{"groupId":"OG004","value":"65.237","spread":null},{"groupId":"OG005","value":"66.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":75},"commonTop":["Rhinitis","Insomnia","Nausea","Irritability","Headache"]}}}